The European Investment Bank (EIB) will provide financing of EUR 25m to AMW GmbH (AMW), a German pharmaceutical company specialised in the development and manufacturing of innovative drug delivery systems. The financing will support AMW in Warngau, Bavaria, and its subsidiary Endomedica in Halle, Saxony-Anhalt, enabling them to increase R&D activities, conduct clinical trials and expand production capacity. This will be achieved with a new building located at the head office in Warngau to house research, development and production facilities complimented by purpose-built manufacturing technology and state-of-the-art laboratory equipment.
This multinational webinar took place on July 11, 2017 in Munich, Tokyo and the Silicon Valley simultaneously. After the presentation, the audience consisting of leading companies and investors from the biopharma and medtech field, could discuss with the originators about their developments.
After a one hour meeting with AMW founder, Dr. Fischer and his management board as well as a subsequent tour through the manufacturing site, Miss Aigner described AMW as the “pearl of the Warngau”.
The products feature innovative injecton devices that exhibit an optimised handling and help to prevent application errors and painful injections.
Warngau, September 8, 2014 – AMW GmbH (Arzneimittelwerk Warngau) has secured follow-up
financing to advance the development and marketing process for its drug delivery systems. BayBG
Bayerische Beteiligungsgesellschaft, UnternehmerTUM Fund and IBG Beteiligungsgesellschaft are
joining existing investors to inject up to seven million euro. The new funds will be used to market
the existing product portfolio and develop a new technology for controlled drug delivery. AMW
GmbH produces active ingredient implants and transdermal systems in the high-growth areas of
oncology, pain therapy and neurology.
-> The whole press release as PDF: english version and german Version
AMW GmbH is an innovative, rapidly expanding specialty pharmaceuticals company located near Munich, Germany. Our R&D expertise is focused on drug delivery systems, especially transdermal delivery systems and biodegradable implants.
Despite significant progress in the treatment of severe diseases with highly active drugs, there are still several unmet needs in various therapeutic areas. Common drug formulations – mainly fast acting tablets, capsules or injections - do not have any control over the drug release properties, what often results in side effects and has a negative impact on patient adherence and efficacy.
The aim of AMW GmbH is to provide therapeutic solutions in strongly growing indications such as
by means of advanced drug delivery systems (DDS). The company focuses on transdermal passive and microchip controlled patches as well as subcutaneous biodegradable implants. The development chain involves, besides technological development, also the clinical development and approval. AMW offers development partnerships with open and transparent collaboration with licensees for exclusive products.